These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 18200508)

  • 21. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation.
    Turecek PL; Bossard MJ; Graninger M; Gritsch H; Höllriegl W; Kaliwoda M; Matthiessen P; Mitterer A; Muchitsch EM; Purtscher M; Rottensteiner H; Schiviz A; Schrenk G; Siekmann J; Varadi K; Riley T; Ehrlich HJ; Schwarz HP; Scheiflinger F
    Hamostaseologie; 2012; 32 Suppl 1():S29-38. PubMed ID: 22961422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pegylated Trastuzumab Fragments Acquire an Increased in Vivo Stability but Show a Largely Reduced Affinity for the Target Antigen.
    Selis F; Focà G; Sandomenico A; Marra C; Di Mauro C; Saccani Jotti G; Scaramuzza S; Politano A; Sanna R; Ruvo M; Tonon G
    Int J Mol Sci; 2016 Apr; 17(4):491. PubMed ID: 27043557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
    Pepinsky RB; LePage DJ; Gill A; Chakraborty A; Vaidyanathan S; Green M; Baker DP; Whalley E; Hochman PS; Martin P
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1059-66. PubMed ID: 11356929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Site-specific PEGylation at histidine tags.
    Cong Y; Pawlisz E; Bryant P; Balan S; Laurine E; Tommasi R; Singh R; Dubey S; Peciak K; Bird M; Sivasankar A; Swierkosz J; Muroni M; Heidelberger S; Farys M; Khayrzad F; Edwards J; Badescu G; Hodgson I; Heise C; Somavarapu S; Liddell J; Powell K; Zloh M; Choi JW; Godwin A; Brocchini S
    Bioconjug Chem; 2012 Feb; 23(2):248-63. PubMed ID: 22243664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative binding of disulfide-bridged PEG-Fabs.
    Khalili H; Godwin A; Choi JW; Lever R; Brocchini S
    Bioconjug Chem; 2012 Nov; 23(11):2262-77. PubMed ID: 22994419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns.
    Zhang X; Wang H; Ma Z; Wu B
    Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1691-702. PubMed ID: 25270687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic consequences of pegylation.
    Hamidi M; Azadi A; Rafiei P
    Drug Deliv; 2006; 13(6):399-409. PubMed ID: 17002967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PEGylation--a well-proven strategy for the improvement of recombinant drugs.
    Zündorf I; Dingermann T
    Pharmazie; 2014 May; 69(5):323-6. PubMed ID: 24855821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tools for predicting the PK/PD of therapeutic proteins.
    Diao L; Meibohm B
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1115-25. PubMed ID: 25936400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.
    Danial M; van Dulmen TH; Aleksandrowicz J; Pötgens AJ; Klok HA
    Bioconjug Chem; 2012 Aug; 23(8):1648-60. PubMed ID: 22770564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physicochemical and pharmacokinetic characterization of highly potent recombinant L-methionine gamma-lyase conjugated with polyethylene glycol as an antitumor agent.
    Takakura T; Takimoto A; Notsu Y; Yoshida H; Ito T; Nagatome H; Ohno M; Kobayashi Y; Yoshioka T; Inagaki K; Yagi S; Hoffman RM; Esaki N
    Cancer Res; 2006 Mar; 66(5):2807-14. PubMed ID: 16510603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects.
    Samtani MN; Perez-Ruixo JJ; Brown KH; Cerneus D; Molloy CJ
    J Clin Pharmacol; 2009 Mar; 49(3):336-50. PubMed ID: 19246731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs.
    Hashimoto Y; Shimizu T; Mima Y; Abu Lila AS; Ishida T; Kiwada H
    Toxicol Appl Pharmacol; 2014 May; 277(1):30-8. PubMed ID: 24632081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-Terminal Modification with Pseudo-Bifunctional PEG-Hexadecane Markedly Improves the Pharmacological Profile of Human Growth Hormone.
    Wu L; Ji S; Hu T
    Mol Pharm; 2015 May; 12(5):1402-11. PubMed ID: 25849255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PEG-modified biopharmaceuticals.
    Bailon P; Won CY
    Expert Opin Drug Deliv; 2009 Jan; 6(1):1-16. PubMed ID: 19236204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. von Willebrand factor contributes to longer half-life of PEGylated factor VIII in vivo.
    Tang L; Leong L; Sim D; Ho E; Gu JM; Schneider D; Feldman RI; Monteclaro F; Jiang H; Murphy JE
    Haemophilia; 2013 Jul; 19(4):539-45. PubMed ID: 23534820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. N-terminal mono-PEGylation of growth hormone antagonist: correlation of PEG size and pharmacodynamic behavior.
    Wu L; Ho SV; Wang W; Gao J; Zhang G; Su Z; Hu T
    Int J Pharm; 2013 Sep; 453(2):533-40. PubMed ID: 23796830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic properties of polyethylene glycol-modified Bacillus thiaminolyticus thiaminase I enzyme.
    Liu S; Bae Y; Leggas M; Daily A; Bhatnagar S; Miriyala S; St Clair DK; Moscow JA
    J Pharmacol Exp Ther; 2012 Jun; 341(3):775-83. PubMed ID: 22431205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
    Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R
    Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polyethylene glycol-drug ester conjugates for prolonged retention of small inhaled drugs in the lung.
    Bayard FJ; Thielemans W; Pritchard DI; Paine SW; Young SS; Bäckman P; Ewing P; Bosquillon C
    J Control Release; 2013 Oct; 171(2):234-40. PubMed ID: 23916883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.